To the 1 January 2025 Does Bendalis GmbH have the product Sugammadex completely including all global distribution rights taken over by Biofactor GmbH. This move marks a significant expansion of our international activities and creates clear, reliable, and long-term prospects for our partners and customers.
With the acquisition, all existing customer relationships, contractual rights, and all relevant sales structures will be transferred to Bendalis – this means: A central point of contact, clear processes, and the highest reliability on delivery, quality and support.
This step opens up additional advantages for our global partners:
- Stable supply capability with direct responsibility and an optimised supply chain
- Uniform sales and quality standards across all markets
- Long-term planning certainty through clear rights and responsibilities
- Extended cooperation possibilities across the entire Bendalis portfolio
By integrating Sugammadex, we are strengthening our international network and consistently continuing our commitment to safe, high-quality, and reliable medicines. We look forward to further expanding our successful collaboration for the benefit of patients – worldwide.